ARTICLE | Company News
Shanghai Junshi licenses anti-PD-1 mAb to CSPC
July 13, 2018 7:58 PM UTC
Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize an undisclosed anti-PD-1 mAb in combination with albumin-bound paclitaxel to treat breast cancer...
BCIQ Target Profiles